Literature DB >> 8757046

Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS.

Y Ikejiri1, E Mori, K Ishii, K Nishimoto, M Yasuda, M Sasaki.   

Abstract

We report a 36-year-old man with MELAS in whom a 5-month course of high-dose oral idebenone, a derivative of coenzyme Q10, increased markedly cerebral metabolic ratio of oxygen and oxygen extraction fraction without increased cerebral blood flow with PET. The results indicate that idebenone improves mitochondrial oxidative metabolism in the brain and suggest a therapeutic potential of idebenone for MELAS.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8757046     DOI： 10.1212/wnl.47.2.583

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  13 in total

1.  Melas syndrome.

Authors:  S K Singh; D Sarin; J M Puliyel; R Srivastav; R Gupta; N Kumar; A Mathews
Journal:  Indian J Pediatr       Date:  1999 Jul-Aug       Impact factor: 1.967

2.  A 41-year-old man with new headache and altered mental status.

Authors:  Erik C B Johnson; Timothy W West; Nerissa U Ko; Jonathan B Strober
Journal:  Neurohospitalist       Date:  2011-01

Review 3.  The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.

Authors:  Fernando Scaglia; Jennifer L Northrop
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  A Strategy for Suppressing Redox Stress within Mitochondria.

Authors:  Pablo M Arce; Omar M Khdour; Ruth Goldschmidt; Jeffrey S Armstrong; Sidney M Hecht
Journal:  ACS Med Chem Lett       Date:  2011-05-31       Impact factor: 4.345

5.  Improved antioxidant effect of idebenone-loaded polyethyl-2-cyanoacrylate nanocapsules tested on human fibroblasts.

Authors:  Maddalena Palumbo; Alessandra Russo; Venera Cardile; Marcella Renis; Donatella Paolino; Giovanni Puglisi; Massimo Fresta
Journal:  Pharm Res       Date:  2002-01       Impact factor: 4.200

Review 6.  Diagnosis and treatment of mitochondrial myopathies.

Authors:  Gerald Pfeffer; Patrick F Chinnery
Journal:  Ann Med       Date:  2011-08-25       Impact factor: 4.709

7.  Features of idebenone and related short-chain quinones that rescue ATP levels under conditions of impaired mitochondrial complex I.

Authors:  Michael Erb; Barbara Hoffmann-Enger; Holger Deppe; Michael Soeberdt; Roman H Haefeli; Christian Rummey; Achim Feurer; Nuri Gueven
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.

Authors:  Roman H Haefeli; Michael Erb; Anja C Gemperli; Dimitri Robay; Isabelle Courdier Fruh; Corinne Anklin; Robert Dallmann; Nuri Gueven
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

9.  The effects of idebenone on mitochondrial bioenergetics.

Authors:  Valentina Giorgio; Valeria Petronilli; Anna Ghelli; Valerio Carelli; Michela Rugolo; Giorgio Lenaz; Paolo Bernardi
Journal:  Biochim Biophys Acta       Date:  2011-11-04

10.  Multiple neurologic, psychiatric, and endocrine complaints in a young woman: a case discussion and review of the clinical features and management of mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke.

Authors:  Chaya G Bhuvaneswar; Jared L Goetz; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.